Bertoli, E.; De Carlo, E.; Del Conte, A.; Stanzione, B.; Revelant, A.; Fassetta, K.; Spina, M.; Bearz, A.
Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It? Int. J. Mol. Sci. 2022, 23, 6936.
https://doi.org/10.3390/ijms23136936
AMA Style
Bertoli E, De Carlo E, Del Conte A, Stanzione B, Revelant A, Fassetta K, Spina M, Bearz A.
Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It? International Journal of Molecular Sciences. 2022; 23(13):6936.
https://doi.org/10.3390/ijms23136936
Chicago/Turabian Style
Bertoli, Elisa, Elisa De Carlo, Alessandro Del Conte, Brigida Stanzione, Alberto Revelant, Kelly Fassetta, Michele Spina, and Alessandra Bearz.
2022. "Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?" International Journal of Molecular Sciences 23, no. 13: 6936.
https://doi.org/10.3390/ijms23136936
APA Style
Bertoli, E., De Carlo, E., Del Conte, A., Stanzione, B., Revelant, A., Fassetta, K., Spina, M., & Bearz, A.
(2022). Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It? International Journal of Molecular Sciences, 23(13), 6936.
https://doi.org/10.3390/ijms23136936